These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3691613)

  • 1. The disposition and metabolism of (+)-cyanidanol-3 in patients with alcoholic cirrhosis.
    Smillie MV; Griffiths LA; Male PJ; Wermeille MM
    Eur J Clin Pharmacol; 1987; 33(3):255-9. PubMed ID: 3691613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism and excretion of (+)-[14C]cyanidanol-3 in man following oral administration.
    Hackett AM; Griffiths LA; Broillet A; Wermeille M
    Xenobiotica; 1983 May; 13(5):279-86. PubMed ID: 6636824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quantitative disposition of 3-O-methyl-(+)-[U-14C]catechin in man following oral administration.
    Hackett AM; Griffiths LA; Wermeille M
    Xenobiotica; 1985 Nov; 15(11):907-14. PubMed ID: 4082631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects].
    Villeneuve JP; Raymond G; Bruneau J; Colpron L; Pomier-Layrargues G
    Gastroenterol Clin Biol; 1983 Nov; 7(11):898-902. PubMed ID: 6653975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevention by (+)-Cyanidanol-3 of hepatitis-induced changes in the disposition of imipramine in the rat.
    Hackett AM; Shaw IC; Griffiths LA
    Biochem Pharmacol; 1984 Jul; 33(14):2179-84. PubMed ID: 6466342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis.
    Owen OE; Trapp VE; Reichard GA; Mozzoli MA; Moctezuma J; Paul P; Skutches CL; Boden G
    J Clin Invest; 1983 Nov; 72(5):1821-32. PubMed ID: 6630528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cimetidine kinetics and dynamics in patients with severe liver disease.
    Villeneuve JP; Fortunet-Fouin H; Arsène D
    Hepatology; 1983; 3(6):923-7. PubMed ID: 6629322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of (-)-epicatechin metabolites and their metabolic fate in the rat.
    Okushio K; Suzuki M; Matsumoto N; Nanjo F; Hara Y
    Drug Metab Dispos; 1999 Feb; 27(2):309-16. PubMed ID: 9929521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some morphometric evidence of hepatoprotective effects of (+)-cyanidanol-3.
    Varga M; Buris L
    Pharmacol Biochem Behav; 1989 Jul; 33(3):523-6. PubMed ID: 2587592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
    Esquivel M; Ogilvie RI; East DS; Shaw DH; Heathcote J
    Clin Invest Med; 1987 Sep; 10(5):363-7. PubMed ID: 3677504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the association of 14C-(+)-cyanidanol-3 with human erythrocytes in vitro.
    Cicurel L; Wermeille M; Golden G; Wachsmuth ED
    Prog Clin Biol Res; 1988; 280():201-4. PubMed ID: 3174692
    [No Abstract]   [Full Text] [Related]  

  • 15. The metabolism and excretion of 3-O-methyl-(+)-catechin in the rat, mouse, and marmoset.
    Hackett AM; Griffiths LA
    Drug Metab Dispos; 1981; 9(1):54-9. PubMed ID: 6111433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine disposition and elimination in cirrhosis.
    Schenker S; Bergstrom RF; Wolen RL; Lemberger L
    Clin Pharmacol Ther; 1988 Sep; 44(3):353-9. PubMed ID: 3262026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of alcoholism and cirrhosis on benzodiazepine receptor function.
    Fluck E; Fernandes C; File SE; Curran HV; Marshall J
    Pharmacol Biochem Behav; 1998 Apr; 59(4):949-54. PubMed ID: 9586854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The disposition of 3-O-methyl-(+)-catechin in the rat and the marmoset following oral administration.
    Hackett AM; Griffiths LA
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):35-42. PubMed ID: 6407839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of paroxetine in patients with cirrhosis.
    Dalhoff K; Almdal TP; Bjerrum K; Keiding S; Mengel H; Lund J
    Eur J Clin Pharmacol; 1991; 41(4):351-4. PubMed ID: 1839532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.